AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.

Abstract

Allon Therapeutics Inc is developing AL-108, an intranasally administered, eight-amino-acid peptide fragment (known as NAP) of activity-dependent neuroprotective protein, and AL-208, an intravenous formulation of NAP. AL-108 is undergoing phase II trials for cognitive impairment in Alzheimer's disease and schizophrenia. AL-108 is also being investigated as a neuroprotective agent, including for the treatment of Parkinson's disease and ocular disease. AL-208 is undergoing phase II clinical trials for the treatment of cognitive disorder and phase I clinical trials for ocular disease and cognitive deficits associated with coronary artery bypass graft or ischemia.

• Authors: Hugo Geerts
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 7 Pg. 800-11 (Jul 2008) ISSN: 1472-4472 [Print] England
• PMID: 18600585 (Publication Type: Journal Article)

Chemical References

• Neuroprotective Agents
• Oligopeptides
• davunetide

Topics

• Animals
• Clinical Trials as Topic
• Cognition Disorders (drug therapy)
• Contraindications
• Drug Evaluation, Preclinical
• Humans
• Neuroprotective Agents (adverse effects, metabolism, pharmacokinetics, therapeutic use, toxicity)
• Oligopeptides (adverse effects, metabolism, pharmacokinetics, therapeutic use, toxicity)
• Patents as Topic
• Schizophrenia (drug therapy)
• Structure-Activity Relationship